65 results on '"Brunner-La Rocca, Hans-Peter"'
Search Results
2. Orthostatic hypotension, cognition and structural brain imaging in hemodynamically impaired patients
- Author
-
Starmans, Naomi L.P., Wolters, Frank J., Leeuwis, Anna E., Bron, Esther E., de Bresser, Jeroen, Brunner-La Rocca, Hans-Peter, Staals, Julie, Muller, Majon, Biessels, Geert Jan, and Kappelle, L. Jaap
- Published
- 2024
- Full Text
- View/download PDF
3. Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?
- Author
-
Steinmann, Eva, Brunner-La Rocca, Hans-Peter, Maeder, Micha T., Kaufmann, Beat A., Pfisterer, Matthias, and Rickenbacher, Peter
- Published
- 2018
- Full Text
- View/download PDF
4. Reliability, construct validity and determinants of 6-minute walk test performance in patients with chronic heart failure
- Author
-
Uszko-Lencer, Nicole H.M.K., Mesquita, Rafael, Janssen, Eefje, Werter, Christ, Brunner-La Rocca, Hans-Peter, Pitta, Fabio, Wouters, Emiel F.M., and Spruit, Martijn A.
- Published
- 2017
- Full Text
- View/download PDF
5. Predicting hospitalization and mortality in patients with heart failure: The BARDICHE-index
- Author
-
Uszko-Lencer, Nicole H.M.K., Frankenstein, Lutz, Spruit, Martijn A., Maeder, Micha T., Gutmann, Marc, Muzzarelli, Stefano, Osswald, Stefan, Pfisterer, Matthias E., Zugck, Christian, and Brunner-La Rocca, Hans-Peter
- Published
- 2017
- Full Text
- View/download PDF
6. Inflammation in HFpEF: Key or circumstantial?
- Author
-
van Empel, Vanessa and Brunner-La Rocca, Hans-Peter
- Published
- 2015
- Full Text
- View/download PDF
7. What kind of patient education and self-care support do patients with heart failure receive, and by whom? Implementation of the ESC guidelines for heart failure in three European regions.
- Author
-
Baldewijns, Karolien, Boyne, Josiane, Rohde, Carla, de Maesschalck, Lieven, Devillé, Aleidis, Brandenburg, Vincent, De Bleser, Leentje, Derickx, Mieke, Bektas, Sema, and Brunner-La Rocca, Hans-Peter
- Abstract
• HF-patient education and self-care support are not a priority for physicians. • If nurses are not available little self-care support takes place. • HF-education and self-care support in primary care is lacking. In order to manage Heart Failure (HF) properly, both pharmacological and non-pharmacological interventions including patient education and self-care (SC) support are important. Appropriate health care (HC) professional support is necessary to improve patient SC-skills. However, little is known which HC-professionals deliver specific education and support in daily HF-care. To describe patient-education and SC-support as perceived by different HC-professionals in three neighboring North-West European regions: Maastricht(the Netherlands), Noorder-Kempen(Belgium), Aachen (Germany). Semi-structured interviews with cardiologists, HF-nurses and general practitioners (GPs) were performed, followed by qualitative content analysis with a five-step approach: 1) familiarization with data, 2) initial coding with an a-priori code manual, 3) structuring of data in main themes, 4) revision and recoding of initial codes and 5) synthesizing codes in main themes. The sample consisted of 15 cardiologists, 35 GPs and 8 HF-nurses. All interviewed HC-professionals provide HF patient-education, yet, the extent differs between them. Whereas HF-nurses identify patient-education and SC-support as one of their main tasks, physicians report that they provide little education. Moreover, little patient education takes place in primary care; with almost none of the GPs reporting to educate patients about SC. GPs in region 2 refer HF-patients to their practice nurse for education and SC-support. None of the HC-professionals reported to provide patients with all key-topics for patient education and SC-support as defined by the ESC. HF nurses consider patient-education and SC-support as one of their main tasks, whereas physicians pay limited attention to education. In none of the three regions, all recommended topics are addressed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Fluid REStriction in Heart Failure vs Liberal Fluid UPtake: Rationale and Design of the Randomized FRESH-UP Study.
- Author
-
Herrmann, Job J., Beckers-Wesche, Fabienne, Baltussen, Lisette E.H.J.M., Verdijk, Marjolein H.I., Bellersen, Louise, Brunner-la Rocca, Hans-Peter, Jaarsma, Tiny, Pisters, Ron, Sanders-van Wijk, Sandra, Rodwell, Laura, Van Royen, Niels, Gommans, D.H. Frank, and Van Kimmenade, Roland R.J.
- Abstract
Aims: It is common practice for clinicians to advise fluid restriction in patients with heart failure (HF), but data from clinical trials are lacking. Moreover, fluid restriction is associated with thirst distress and may adversely impact quality of life (QoL). To address this gap in evidence, the Fluid REStriction in Heart failure vs liberal fluid UPtake (FRESH-UP) study was initiated.Methods: The FRESH-UP study is a randomized, controlled, open-label, multicenter trial to investigate the effects of a 3-month period of liberal fluid intake vs fluid restriction (1500 mL/day) on QoL in outpatients with chronic HF (New York Heart Association Classes II--III). The primary aim is to assess the effect on QoL after 3 months using the Overall Summary Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ). Thirst distress, as assessed by the Thirst Distress Scale for patients with HF, KCCQ Clinical Summary Score, each of the KCCQ domains and clinically meaningful changes in these scores, the EQ-5D-5L, patient-reported fluid intake and safety (ie, death, HF hospitalizations) are secondary outcomes. The FRESH-UP study is registered at ClinicalTrials.gov (NCT04551729).Conclusion: The results of the FRESH-UP study will add substantially to the level of evidence concerning fluid management in chronic HF and may impact the QoL of these patients. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.
- Author
-
Verdonschot, Job A.J., Ferreira, JoÃo Pedro, Pizard, Anne, Pellicori, Pierpaolo, Brunner La Rocca, Hans-Peter, Clark, Andrew L., Cosmi, Franco, Cuthbert, Joe, Girerd, Nicolas, Waring, Olivia J., Henkens, Michiel H.T.M., Mariottoni, Beatrice, Petutschnigg, Johannes, Rossignol, Patrick, Hazebroek, Mark R., Cleland, John G.F., Zannad, Faiez, Heymans, Stephane R.B., and HOMAGE “Heart Omics in AGEing” Consortium
- Abstract
Background: Adipose tissue influences the expression and degradation of circulating biomarkers. We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone.Methods and Results: Protein biomarkers (n = 276) from the Olink Proseek-Multiplex cardiovascular and inflammation panels were measured in plasma collected at baseline, 1 month and 9 months from the HOMAGE randomized controlled trial participants. Of the 510 participants, 299 had obesity defined as an increased waist circumference (≥102 cm in men and ≥88 cm in women). Biomarkers at baseline reflected adipogenesis, increased vascularization, decreased fibrinolysis, and glucose intolerance in patients with obesity at baseline. Treatment with spironolactone had only minor effects on this proteomic profile. Obesity modified the effect of spironolactone on systolic blood pressure (Pinteraction = 0.001), showing a stronger decrease of blood pressure in obese patients (-14.8 mm Hg 95% confidence interval -18.45 to -11.12) compared with nonobese patients (-3.6 mm Hg 95% confidence interval -7.82 to 0.66).Conclusions: Among patients at risk for heart failure, those with obesity have a characteristic proteomic profile reflecting adipogenesis and glucose intolerance. Spironolactone had only minor effects on this obesity-related proteomic profile, but obesity significantly modified the effect of spironolactone on systolic blood pressure. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
10. Management of elderly patients with congestive heart failure--design of the trail of intensified versus standard Medical therapy in elderly patients with Congestive Heart Failure (TIME-CHF)
- Author
-
Brunner-La Rocca, Hans Peter, Buser, Peter Theo, Schindler, Ruth, Bernheim, Alain, Rickenbacher, Peter, and Pfisterer, Matthias
- Subjects
Aged patients -- Health aspects ,Aged patients -- Care and treatment ,Congestive heart failure -- Management ,Therapeutics -- Research ,Therapeutics -- Management ,Homeopathy -- Materia medica and therapeutics ,Homeopathy -- Research ,Homeopathy -- Management ,Company business management ,Health - Published
- 2006
11. Inflammation and long-term mortality in acute congestive heart failure
- Author
-
Mueller, Christian, Laule-Kilian, Kirsten, Christ, Andreas, Brunner-La Rocca, Hans Peter, and Perruchoud, Andre P.
- Subjects
Congestive heart failure -- Patient outcomes ,Cardiac patients -- Prognosis ,Inflammation -- Influence ,Inflammation -- Research ,Mortality -- Risk factors ,Mortality -- Research ,C-reactive protein -- Analysis ,Health - Published
- 2006
12. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET)
- Author
-
Kaiser, Christoph, Brunner-La Rocca, Hans Peter, Buser, Peter T., Bonetti, Piero O., Osswald, Stefan, Linka, Andre, Bernheim, Alain, Zutter, Andreas, Zellweger, Michael, Grize, Leticia, and Pfisterer, Matthias E.
- Subjects
Stent (Surgery) -- Evaluation ,Stent (Surgery) -- Complications and side effects ,Stent (Surgery) -- Usage - Published
- 2005
13. Myocardial Fibrosis Assessment Using T1 and ECV Mapping With Histologic Validation in Chronic Dilated Cardiomyopathy.
- Author
-
Raafs, Anne G., Adriaans, Bouke P., Henkens, Michiel T.H.M., Verdonschot, Job A.J., Ramaekers, Mitch J.F.G., Gommers, Suzanne, Abdul Hamid, Myrurgia A., Schalla, Simon, Knackstedt, Christian, van Empel, Vanessa.P.M., Brunner-la Rocca, Hans-Peter, Wildberger, J.E., Bekkers, Sebastiaan C.A.M., and Hazebroek, Mark R.
- Published
- 2022
- Full Text
- View/download PDF
14. Prolonged oxygen uptake kinetics during low-intensity exercise are related to poor prognosis in patients with mild-to-moderate congestive heart failure *
- Author
-
Schalcher, Christoph, Rickli, Hans, Brehm, Manuel, Weilenmann, Daniel, Oechslin, Erwin, Kiowski, Wolfgang, and Brunner-La Rocca, Hans Peter
- Subjects
Exercise -- Physiological aspects ,Congestive heart failure -- Prognosis -- Research ,Oxygen consumption -- Physiological aspects -- Research ,Exercise tests -- Evaluation -- Research -- Physiological aspects ,Statistics -- Physiological aspects -- Research ,Health ,Evaluation ,Physiological aspects ,Research ,Prognosis - Abstract
Study objective: To investigate the prognostic value of oxygen uptake (V[O.sub.2]) kinetics during low-intensity exercise in patients with congestive heart failure. Design: Prospective cohort study. Setting: Tertiary care center. Patients: [...]
- Published
- 2003
15. Noninvasive assessment of cardiac pumping capacity during exercise predicts prognosis in patients with congestive heart failure *. (clinical investigations)
- Author
-
Scharf, Christoph, Merz, Tobias, Kiowski, Wolfgang, Oechslin, Erwin, Schalcher, Christoph, and Brunner-La Rocca, Hans Peter
- Subjects
Exercise -- Analysis -- Physiological aspects -- Measurement ,Cardiac output -- Analysis -- Measurement -- Physiological aspects ,Mortality -- Switzerland -- United States ,Congestive heart failure -- Patient outcomes ,Health ,Analysis ,Physiological aspects ,Measurement ,Patient outcomes - Abstract
Background: Prognostic parameters in patients with congestive heart failure (CHF) are important for guiding therapeutic options. Maximal oxygen uptake (V[O.sub.2]max) is a widely used parameter for prognostic assessment in patients [...]
- Published
- 2002
16. Noninvasive evaluation of pulmonary capillary wedge pressure by BP response to the Valsalva maneuver *
- Author
-
Weilenmann, Daniel, Rickli, Hans, Follath, Ferenc, Kiowski, Wolfgang, and Brunner-La Rocca, Hans Peter
- Subjects
Congestive heart failure -- Care and treatment ,Valsalva's maneuver -- Physiological aspects ,Health ,Care and treatment ,Physiological aspects - Abstract
Study objectives: To determine the BP response to the Valsalva maneuver (VM) at baseline and after changes in therapy and to compare this response to the invasively measured pulmonary capillary [...]
- Published
- 2002
17. Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment.
- Author
-
Amier, Raquel P., Marcks, Nick, Hooghiemstra, Astrid M., Nijveldt, Robin, van Buchem, Mark A., de Roos, Albert, Biessels, Geert Jan, Kappelle, L. Jaap, van Oostenbrugge, Robert J., van der Geest, Rob J., Bots, Michiel L., Greving, Jacoba P., Niessen, Wiro J., van Osch, Matthias J.P., de Bresser, Jeroen, van de Ven, Peter M., van der Flier, Wiesje M., Brunner-La Rocca, Hans-Peter, and van Rossum, Albert C.
- Abstract
This study sought to investigate the extent of hypertensive exposure as assessed by cardiovascular magnetic resonance imaging (MRI) in relation to cerebral small vessel disease (CSVD) and cognitive impairment, with the aim of understanding the role of hypertension in the early stages of deteriorating brain health. Preserving brain health into advanced age is one of the great challenges of modern medicine. Hypertension is thought to induce vascular brain injury through exposure of the cerebral microcirculation to increased pressure/pulsatility. Cardiovascular MRI provides markers of (subclinical) hypertensive exposure, such as aortic stiffness by pulse wave velocity (PWV), left ventricular (LV) mass index (LVMi), and concentricity by mass-to-volume ratio. A total of 559 participants from the Heart-Brain Connection Study (431 patients with manifest cardiovascular disease and 128 control participants), age 67.8 ± 8.8 years, underwent 3.0-T heart-brain MRI and extensive neuropsychological testing. Aortic PWV, LVMi, and LV mass-to-volume ratio were evaluated in relation to presence of CSVD and cognitive impairment. Effect modification by patient group was investigated by interaction terms; results are reported pooled or stratified accordingly. Aortic PWV (odds ratio [OR]: 1.17; 95% confidence interval [CI]: 1.05 to 1.30 in patient groups only), LVMi (in carotid occlusive disease, OR: 5.69; 95% CI: 1.63 to 19.87; in other groups, OR: 1.30; 95% CI: 1.05 to 1.62]) and LV mass-to-volume ratio (OR: 1.81; 95% CI: 1.46 to 2.24) were associated with CSVD. Aortic PWV (OR: 1.07; 95% CI: 1.02 to 1.13) and LV mass-to-volume ratio (OR: 1.27; 95% CI: 1.07 to 1.51) were also associated with cognitive impairment. Relations were independent of sociodemographic and cardiac index and mostly persisted after correction for systolic blood pressure or medical history of hypertension. Causal mediation analysis showed significant mediation by presence of CSVD in the relation between hypertensive exposure markers and cognitive impairment. The extent of hypertensive exposure is associated with CSVD and cognitive impairment beyond clinical blood pressure or medical history. The mediating role of CSVD suggests that hypertension may lead to cognitive impairment through the occurrence of CSVD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. Atrial fibrillation in chronic heart failure patients with reduced ejection fraction: The CHECK-HF registry.
- Author
-
Veenis, Jesse F., Brunner-La Rocca, Hans-Peter, Linssen, Gerard C.M., Smeele, Frank J.J., Wouters, Noëmi T.A.E., Westendorp, Paul H.M., Rademaker, Philip C., Hemels, Martin E.W., Rienstra, Michiel, Hoes, Arno W., and Brugts, Jasper J.
- Subjects
- *
VENTRICULAR fibrillation , *ATRIAL fibrillation , *HEART failure patients , *VENTRICULAR ejection fraction , *PHARMACOLOGY - Abstract
Atrial fibrillation (AF) is common in chronic heart failure (HF) patients and influences the choice and effects of drug and device therapy. In this large real-world HF registry, we studied whether the presence of AF affects the prescription of guideline-recommended HF therapy. We analyzed 8253 patients with chronic HF with reduced ejection fraction (HFrEF) from 34 Dutch outpatient clinics included in the period between 2013 and 2016 treated according to the 2012 ESC guidelines. 2109 (25.6%) of these patients were in AF (mean age 76.8 ± 9.2 years, 65.0% were men) and 6.144 (74.4%) had no AF (mean age 70.7 ± 12.2 years, 63.6% were men). Patients with AF more often received beta-blockers (81.7% vs. 79.7%, p = 0.04), MRAs (57.1% vs. 51.7%, p < 0.01), diuretics (89.7% vs. 80.6%, p < 0.01) and digoxin (40.1% vs. 9.3%, p < 0.01) compared to patients without AF, whereas they less often receive renin-angiotensin-system (RAS)-inhibitors (76.1% vs. 83.1%, p < 0.01). The number of patients who received beta-blockers, RAS-inhibitor and MRA at ≥50% of the recommended target dose was comparable between those with and without AF (16.6% vs. 15.2%, p = 0.07). In this large cohort of chronic HFrEF patients, the prevalence of AF was high and we observed significant differences in prescription of both guideline-recommended HF between patients with and without AF. • HFrEF patients with AF received more often beta-blockers, MRA, diuretics and digoxin. • HFrEF patients with AF received less often RAS-inhibitors. • More insight in the efficacy and adherence of HF therapy in AF patients is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Value of Speckle Tracking–Based Deformation Analysis in Screening Relatives of Patients With Asymptomatic Dilated Cardiomyopathy.
- Author
-
Verdonschot, Job A.J., Merken, Jort J., Brunner-La Rocca, Hans-Peter, Hazebroek, Mark R., Eurlings, Casper G.M.J., Thijssen, Eline, Wang, Ping, Weerts, Jerremy, van Empel, Vanessa, Schummers, Georg, Schreckenberg, Marcus, van den Wijngaard, Arthur, Lumens, Joost, Brunner, Han G., Heymans, Stephane R.B., Krapels, Ingrid P.C., and Knackstedt, Christian
- Abstract
This study sought to investigate the prevalence of systolic dysfunction using global longitudinal strain (GLS) and its prognostic value in relatives of dilated cardiomyopathy (DCM) patients that had normal left ventricular ejection fraction (LVEF). DCM relatives are advised to undergo cardiac assessment including echocardiography, irrespective of the genetic status of the index patient. Even though LVEF is normal, the question remains whether this indicates absence of disease or simply normal cardiac volumes. GLS may provide additional information regarding (sub)clinical cardiac abnormalities and thus allow earlier disease detection. A total of 251 DCM relatives and 251 control subjects with a normal LVEF (≥55%) were screened. Automated software measured the GLS on echocardiographic 2-, 3-, and 4-chamber views. The cutoff value for abnormal strain was >−21.5. Median follow-up was 40 months (interquartile range: 5 to 80 months). Primary outcome was the combination of death and cardiac hospitalization. A total of 120 relatives and 83 control subjects showed abnormal GLS (48% vs. 33%, respectively; p < 0.001). Abnormal GLS was independently associated with DCM relatives and cardiovascular risk factors, rather than genetic mutations. Subjects with abnormal GLS had more frequent cardiac hospitalizations and a higher mortality as compared with subjects with normal GLS (hazard ratio: 3.29; 95% confidence interval: 1.58 to 6.87; p = 0.001). Additionally, follow-up LVEF was measured in a subset of relatives, and it decreased significantly in those with abnormal as compared with normal GLS (p = 0.006). Relatives of DCM patients had a significantly higher prevalence of systolic dysfunction detected by GLS despite normal LVEF compared with control subjects, independent of age, sex, comorbidities, and genotype. Abnormal GLS was associated with LVEF deterioration, cardiac hospitalization, and death. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Interaction of angiotensin-converting enzyme inhibition and aspirin in congestive heart failure: long controversy finally resolved?
- Author
-
Brunner-La Rocca, Hans Peter
- Subjects
Aspirin -- Influence -- Physiological aspects ,Congestive heart failure -- Drug therapy ,ACE inhibitors -- Influence -- Physiological aspects ,Drug interactions -- Physiological aspects ,Health ,Influence ,Drug therapy ,Physiological aspects - Abstract
Not long after the initial findings of the positive effects of angiotensin-converting enzyme (ACE) inhibition on prognosis for patients with congestive heart failure (CHF), a controversy commenced as to whether [...]
- Published
- 2003
21. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
- Author
-
Davarzani, Nasser, Sanders–van Wijk, Sandra, Karel, Joël, Maeder, Micha T., Leibundgut, Gregor, Gutmann, Marc, Pfisterer, Matthias E., Rickenbacher, Peter, Peeters, Ralf, Brunner–la Rocca, Hans-Peter, Sanders-van Wijk, Sandra, and Brunner-la Rocca, Hans-Peter
- Abstract
Background: Although heart failure (HF) patients are known to experience repeated hospitalizations, most studies evaluated only time to first event. N-Terminal B-type natriuretic peptide (NT-proBNP)-guided therapy has not convincingly been shown to improve HF-specific outcomes, and effects on recurrent all-cause hospitalization are uncertain. Therefore, we investigated the effect of NT-proBNP-guided therapy on recurrent events in HF with the use of a time-between-events approach in a hypothesis-generating analysis.Methods and Results: The Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized 499 HF patients, aged ≥60 years, left ventricular ejection fraction ≤45%, New York Heart Association functional class ≥I,I to NT-proBNP-guided versus symptom-guided therapy for 18 months, with further follow-up for 5.5 years. The effect of NT-proBNP-guided therapy on recurrent HF-related and all-cause hospitalizations and/or all-cause death was explored. One hundred four patients (49 NT-proBNP-guided, 55 symptom-guided) experienced 1 and 275 patients (133 NT-proBNP-guided, 142 symptom-guided) experienced ≥2 all-cause hospitalization events. Regarding HF hospitalization, 132 patients (57 NT-proBNP-guided, 75 symptom-guided) experienced 1 and 122 patients (57 NT-proBNP-guided, 65 symptom-guided) experienced ≥2 events. NT-proBNP-guided therapy was significant in preventing 2nd all-cause hospitalizations (hazard ratio [HR] 0.83; P = .01), in contrast to nonsignificant results in preventing 1st all-cause hospitalization events (HR 0.91; P = .35). This was not the case regarding HF hospitalization events (HR 0.85 [P = .14] vs HR 0.73 [P = .01]) The beneficial effect of NT-proBNP-guided therapy was seen only in patients aged <75 years, and not in those aged ≥75 years (interaction terms with P = .01 and P = .03 for all-cause hospitalization and HF hospitalization events, respectively).Conclusion: NT-proBNP-guided therapy reduces the risk of recurrent events in patients <75 years of age. This included all-cause hospitalization by mainly reducing later events, adding knowledge to the neutral effect on this end point when shown using time-to-first-event analysis only.Clinical Trial Registration: isrctn.org, identifier: ISRCTN43596477. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
22. Guiding Heart Failure Therapy After GUIDE-IT: Back to the Drawing Board.
- Author
-
Brunner-La Rocca, Hans-Peter and Sanders-van Wijk, Sandra
- Subjects
- *
HEART failure , *QUALITY of life , *NATRIURETIC peptides - Published
- 2018
- Full Text
- View/download PDF
23. Cost-Effectiveness Benefits of a Disease Management Program:The REMADHE Trial Results.
- Author
-
Bocchi, Edimar Alcides, da Cruz, FÁtima das Dores, BrandÃo, Sara Michelly, Issa, Victor, Ayub-Ferreira, Silvia Moreira, la Rocca, Hans-Peter Brunner, Wijk, Sandra Sanders–van, da Cruz, Fátima das Dores, Brandão, Sara Michelly, Wijk, Sandra Sanders-van, and Brunner la Rocca, Hans-Peter
- Abstract
Background: Published studies have generated mixed, controversial results regarding the cost-effectiveness of heart failure disease management programs (HF-DMPs). This study assessed the cost-effectiveness of an HF-DMP in ambulatory patients compared with usual care (UC).Methods: In the prospective randomized REMADHE trial, we evaluated incremental costs per quality-adjusted life-year (QALY) and life-year (LY) gained as effectiveness ratios (ICERs) over a study period of 2.47 ± 1.75 years.Results: The REMADHE HF-DMP was more effective and less costly than UC in terms of both QALYs and LYs (95% and 55% chance of dominance, respectively). Average saving was US$7345 (2.5%-97.5% bootstrapped confidence interval -16,573 to +921). The chance of DMP being cost-effective at a willingness to pay US$10,000 per QALY or LY was 99% and 96%, respectively. Cost-effectiveness of HF-DMP was highest in subgroups with left ventricular ejection fraction <35%, age >50 years, male sex, New York Heart Association (NYHA) functional class ≥III, and ischemic etiology. The chance of DMP being cost-effective at a willingness to pay US$10,000 per QALY was ≥90% in all subgroups apart from NYHA functional class I-II, where it was 70%. Even when the intervention costs increased by 500% or when excluding outliers in costs, DMP had a high chance of being cost-effective (87%-99%).Conclusions: The HF-DMP of the REMADHE trial, which encompasses long-term repeated education alongside telephone monitoring, has a high probability of being cost-effective in ambulatory patients with HF. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. Differential Prognostic Impact of Resting Heart Rate in Older Compared With Younger Patients With Chronic Heart Failure—Insights From TIME-CHF.
- Author
-
Zurek, Marzena, Maeder, Micha T., Rickli, Hans, Muzzarelli, Stefano, Sanders-van Wijk, Sandra, Abbühl, Heidi, Handschin, Rolf, Jeker, Urs, Pfisterer, Matthias, and Brunner-la Rocca, Hans-Peter
- Abstract
Background There is little information regarding the prognostic role of resting heart rate (HR) in older compared with younger patients with chronic heart failure (HF). Methods and Results In patients enrolled in the Trial of Intensified Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) with sinus rhythm, effects of baseline HR (≥70 vs <70 beats/min [bpm]) on 18-month outcomes were compared between older (≥75 years; n = 186) and younger (<75 years; n = 141) patients. Older patients with lower (61 ± 6 bpm) and higher (83 ± 9 bpm) HR had similar left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, N-terminal pro–B-type natriuretic peptide (NT-proBNP), and survival and HF hospitalization–free survival. In contrast, younger patients with higher HR (81 ± 7 bpm) had higher NT-proBNP and NYHA functional class, lower LVEF, and a higher risk of death (hazard ratio 4.01 [95% confidence interval (CI) 1.17 −13.69]; P = .02) and death or HF hospitalization (hazard ratio 2.35 [95% CI 1.01–5.50]; P = .04) than those with lower HR (62 ± 5 bpm), with the association between higher HR and survival remaining significant after adjustment for NYHA functional class, LVEF, and NT-proBNP. Conclusions In contrast to HF patients aged <75 years, we found no association between HR and worse outcomes in HF patients aged ≥75 years. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. Risk Stratification With the Use of Serial N-Terminal Pro-B-Type Natriuretic Peptide Measurements During Admission and Early After Discharge in Heart Failure Patients: Post Hoc Analysis of the PRIMA Study.
- Author
-
Eurlings, Luc W, Sanders-van Wijk, Sandra, van Kraaij, Dave J W, van Kimmenade, Roland, Meeder, Joan G, Kamp, Otto, van Dieijen-Visser, Marja P, Tijssen, Jan G P, Brunner-La Rocca, Hans-Peter, and Pinto, Yigal M
- Abstract
OBJECTIVE: The aim of this work was to assess the prognostic value of absolute N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration in combination with changes during admission because of acute heart failure (AHF) and early after hospital discharge. BACKGROUND: In AHF, readmission and mortality rates are high. Identifying those at highest risk for events early after hospital discharge might help to select patients in need of intensive outpatient monitoring. METHODS AND RESULTS: We evaluated the prognostic value of NT-proBNP concentration on admission, at discharge, 1 month after hospital discharge and change over time in 309 patients included in the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Primary outcome measures were mortality and the combined end point of heart failure (HF) readmission or mortality. In a multivariate Cox regression analysis, change in NT-proBNP concentration during admission, change from discharge to 1 month after discharge, and the absolute NT-proBNP concentration at 1 month after discharge were of independent prognostic value for both end points (hazard ratios for HF readmission or mortality: 1.71, 95% confidence interval [CI] 1.13-2.60, Wald 6.4 [P = .011] versus 2.71, 95% CI 1.76-4.17, Wald 20.5 [P < .001] versus 1.81, 95% CI 1.13-2.89, Wald 6.1 [P = .014], respectively. CONCLUSIONS: Knowledge of change in NT-proBNP concentration during admission because of AHF in combination with change early after discharge and the absolute NT-proBNP concentration at 1 month after discharge allows accurate risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
26. Interaction Between Pulmonary Hypertension and Diastolic Dysfunction in an Elderly Heart Failure Population.
- Author
-
VAN EMPEL, VANESSA P. M., KAUFMANN, BEAT A., BERNHEIM, ALAIN M., GOETSCHALCKX, KAATJE, SON Y. MIN, MUZZARELLI, STEFANO, PFISTERER, MATTHIAS E., KIENCKE, STEPHANIE, MAEDER, MICHA T., and BRUNNER-LA ROCCA, HANS-PETER
- Abstract
Background: Pulmonary hypertension due to left heart disease is very common. Our aim was to investigate the relationship of the severity of left ventricular diastolic dysfunction with precapillary and postcapillary pulmonary hypertension (PH) in an elderly heart failure (HF) population. Methods and Results: A post hoc analysis of the Trial of Intensified Medical Therapy in Elderly Patients With Congestive Heart Failure data was done. Baseline transthoracic echocardiography was used to categorize diastolic function, estimate pulmonary artery pressure and pulmonary capillary wedge pressure, and calculate the transpulmonary pressure gradient (TPG). Among 392 HF patients, PH was present in 31% of patients with grade 1, in 37% of patients with grade 2, and in 65% of patients with grade 3 diastolic dysfunction; 54% of all HF patients with PH had a TPG > 12 mm Hg, suggesting not only a postcapillary but also an additional precapillary component of PH. Survival was not related to the severity of diastolic dysfunction, but was worse in patients with PH (hazard ratio 1.63, 95% confidence interval 1.07-2.51; P = .024). Conclusions: Our data indicate that HF patients with even mild diastolic dysfunction often have PH. Echocardiographie assessment suggest that the presence of PH might not simply be due to increased PCWR but in part due to a precapillary component. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. The role of cardiovascular magnetic resonance imaging and computed tomography angiography in suspected non-ST-elevation myocardial infarction patients: Design and rationale of the CARdiovascular Magnetic rEsoNance imaging and computed Tomography...
- Author
-
Smulders, Martijn W, Kietselaer, Bastiaan L J H, Das, Marco, Wildberger, Joachim E, Crijns, Harry J G M, Veenstra, Leo F, Brunner-La Rocca, Hans-Peter, van Dieijen-Visser, Marja P, Mingels, Alma M A, Dagnelie, Pieter C, Post, Mark J, Gorgels, Anton P M, van Asselt, Antoinette D I, Vogel, Gaston, Schalla, Simon, Kim, Raymond J, and Bekkers, Sebastiaan C A M
- Published
- 2013
- Full Text
- View/download PDF
28. NADPH oxidase-dependent oxidative stress in the failing heart: From pathogenic roles to therapeutic approach
- Author
-
Octavia, Yanti, Brunner-La Rocca, Hans Peter, and Moens, An L.
- Subjects
- *
HEART failure risk factors , *MYOCARDIAL infarction , *INFLAMMATION , *DIABETES , *HEART fibrosis , *HEART dilatation , *OXIDATIVE stress , *NICOTINAMIDE adenine dinucleotide phosphate - Abstract
Abstract: Heart failure (HF) occurs when the adaptation mechanisms of the heart fail to compensate for stress factors, such as pressure overload, myocardial infarction, inflammation, diabetes, and cardiotoxic drugs, with subsequent ventricular hypertrophy, fibrosis, myocardial dysfunction, and chamber dilatation. Oxidative stress, defined as an imbalance between reactive oxygen species (ROS) generation and the capacity of antioxidant defense systems, has been authenticated as a pivotal player in the cardiopathogenesis of the various HF subtypes. The family of NADPH oxidases has been investigated as a key enzymatic source of ROS in the pathogenesis of HF. In this review, we discuss the importance of NADPH oxidase-dependent ROS generation in the various subtypes of HF and its implications. A better understanding of the pathogenic roles of NADPH oxidases in the failing heart is likely to provide novel therapeutic strategies for the prevention and treatment of HF. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
29. Predictors of early readmission or death in elderly patients with heart failure.
- Author
-
Muzzarelli, Stefano, Leibundgut, Gregor, Maeder, Micha T., Rickli, Hans, Handschin, Rolf, Gutmann, Marc, Jeker, Urs, Buser, Peter, Pfisterer, Matthias, and Brunner-La Rocca, Hans-Peter
- Abstract
Background: Contemporary heart failure (HF) patients are elderly and have a high rate of early rehospitalization or death, resulting in a high burden for both the patients and the health care system. Prior studies were focused on younger and less well-characterized patients. We aimed to identify predictors of early hospital readmission and death in elderly patients with HF. Methods: Patients with chronic HF taking part in the TIME-CHF study (n = 614, age 77 ± 8 years, 41% female, left ventricular ejection fraction 35% ± 13%) were evaluated with respect to predictors of hospital readmission or death 30 and 90 days after inclusion. Demographic, clinical, laboratory, echocardiographic, and social variables were obtained at baseline and included in a multivariable logistic regression analysis to identify predictors of early events. Results: The rate of hospital readmission or death was high at 30 (11%) and 90 days (26%). The reason for hospitalization was HF in 33%, other cardiovascular in 32%, and noncardiovascular in 45% of the cases, respectively. Predictors of readmission or death at 30 days were angina, lower systolic blood pressure, anemia, more extensive edema, higher creatinine levels, and dry cough; and at 90 days were coronary artery disease, prior pacemaker implantation, high jugular venous pressure, pulmonary rales, prior abdominal surgery, older age, and depressive symptoms. Conclusions: Early hospital readmission or death was frequent among elderly HF patients. A very large proportion of readmissions were due to noncardiovascular causes. In addition to clinical signs of HF, comorbidities are important predictors of early events in elderly HF patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
30. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: A retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial
- Author
-
Jeger, Raban V., Brunner-La Rocca, Hans Peter, Hunziker, Patrick R., Tsakiris, Dimitrios A., Kaiser, Christoph A., and Pfisterer, Matthias E.
- Subjects
- *
SURGICAL stents , *GLYCOPROTEINS , *THROMBOSIS , *ABCIXIMAB (Drug) , *TIROFIBAN , *CORONARY heart disease treatment - Abstract
Background: Drug-eluting stents (DESs) are associated with late stent thromboses, but the exact mechanism of action is unknown. Objective: The goal of this article was to assess the clinical interaction of glycoprotein IIb/IIIa inhibitors (GPIs) with different stent and vessel types in unselected patients undergoing percutaneous coronary intervention (PCI). Methods: This was a predefined retrospective analysis of the randomized controlled Basel Stent Kosten Effektivitats Trial (BASKET), which compared DES with bare-metal stents (BMSs) in patients undergoing PCI. Patients were compared for major adverse clinical events in relation to GPI use (abciximab and tirofiban) after 18 months. In a subgroup analysis prespecified in the study protocol, specific regard was given to angiographic groups at different risk levels for late events (high-risk vessels [ie, small vessels with a diameter <3.0 mm and saphenous vein grafts], and low-risk vessels [ie, large native vessels ≥3.0 mm]). Baseline differences between patients with or without GPI use were identified and incorporated into a multivariable Cox proportional hazards regression analysis if different at a <0.05 level. Results: A total of 826 patients (650 males, 176 females) were enrolled in BASKET; 301 (36%) received GPI therapy. Of these 301 patients, 255 (85%) received abciximab and 46 (15%) received tirofiban. After 18 months, the rate of cardiac death and nonfatal myocardial infarction was higher in patients with GPI use than in those without GPI use (35/301 [12%] vs 32/525 [6%]; P = 0.005). In patients undergoing PCI in anatomically low-risk vessels and receiving GPI therapy, there was a higher rate of cardiac death and nonfatal myocardial infarction at 18 months with a DES versus a BMS (22/151 [15%] vs 3/66 [5%]; P = 0.033). In patients undergoing PCI in anatomically low-risk vessels and without GPI therapy, there was no significant difference for cardiac death and nonfatal myocardial infarction (DES vs BMS, 11/207 [5%] vs 6/134 [4%]). In the multivariable analysis, GPI use (hazard ratio = 2.93; 95% CI, 1.53-5.63; P = 0.001) and age (hazard ratio = 1.034 per year increase; 95% CI, 1.008-1.062; P = 0.012) remained the only significant independent predictors of outcome. Interaction of stent type and GPI use was significant (P = 0.006). Conclusions: This retrospective analysis of the BASKET data found that GPIs and DESs used in patients with large native vessels may have an adverse interaction in terms of late stent thromboses. However, large prospective studies are needed to confirm these findings. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
31. Drug-eluting or bare-metal stents forlarge coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: Study protocol and design.
- Author
-
Pfisterer, Matthias, Bertel, Osmund, Bonetti, Piero O., Brunner-La Rocca, Hans Peter, Eberli, Franz R., Erne, Paul, Galatius, Soeren, Hornig, Burkhard, Kiowski, Wolfgang, Pachinger, Otmar, Pedrazzini, Giovanni, Rickli, Hans, De Servi, Stefano, and Kaiser, Christoph
- Subjects
SURGICAL stents ,THROMBOSIS ,HYPOTHESIS ,CHROMIUM - Abstract
Background: Based on a subgroup analysis of 18-month BAsel Stent Kosten Effektivitäts Trial (BASKET) outcome data, we hypothesized that very late (>12 months) stent thrombosis occurs predominantly after drug-eluting stent implantation in large native coronary vessel stenting. Methods: To prove or refute this hypothesis, we set up an 11-center 4-country prospective trial of 2260 consecutive patients treated with ≥3.0-mm stents only, randomized to receive Cypher (Johnson & Johnson, Miami Lakes, FL), Vision (Abbott Vascular, Abbott Laboratories, IL), or Xience stents (Abbott Vascular). Only patients with left main or bypass graft disease, in-stent restenosis or stent thrombosis, in need of nonheart surgery, at increased bleeding risk, without compliance/consent are excluded. All patients are treated with dual antiplatelet therapy for 12 months. The primary end point will be cardiac death/nonfatal myocardial infarction after 24 months with further follow-up up to 5 years. Results: By June 12, 229 patients (10% of the planned total) were included with a baseline risk similar to that of the same subgroup of BASKET (n = 588). Conclusions: This study will answer several important questions of contemporary stent use in patients with large native vessel stenting. The 2-year death/myocardial infarction—as well as target vessel revascularization—and bleeding rates in these patients with a first- versus second-generation drug-eluting stent should demonstrate the benefit or harm of these stents compared to cobalt-chromium bare-metal stents in this relevant, low-risk group of everyday patients. In addition, a comparison with similar BASKET patients will allow to estimate the impact of 12- versus 6-month dual antiplatelet therapy on these outcomes. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
32. What do we need to better understand the role of biomarkers in heart failure?
- Author
-
Brunner-La Rocca, Hans-Peter
- Subjects
- *
HEART failure , *NATRIURETIC peptides , *BIOLOGICAL tags - Published
- 2020
- Full Text
- View/download PDF
33. Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting Versus Bare-Metal Stents
- Author
-
Pfisterer, Matthias, Brunner-La Rocca, Hans Peter, Buser, Peter T., Rickenbacher, Peter, Hunziker, Patrick, Mueller, Christian, Jeger, Raban, Bader, Franziska, Osswald, Stefan, and Kaiser, Christoph
- Subjects
- *
THROMBOSIS , *BLOOD coagulation , *MYOCARDIAL revascularization , *MYOCARDIAL infarction - Abstract
Objectives: We sought to define the incidence of late clinical events and late stent thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after the discontinuation of clopidogrel as well as their timing and outcome. Background: There is growing concern that delayed endothelialization after DES implantation may lead to late stent thrombosis and related myocardial infarction (MI) or death. However, event rates and outcomes after clopidogrel discontinuation versus BMS are unknown. Methods: A consecutive series of 746 nonselected patients with 1,133 stented lesions surviving 6 months without major events were followed for 1 year after the discontinuation of clopidogrel. Patients were assigned randomly 2:1 to DES versus BMS in BASKET (Basel Stent Kosten Effektivitäts Trial). The primary focus of this observation was cardiac death/MI. Results: Rates of 18-month cardiac death/MI were not different between DES and BMS patients. However, after the discontinuation of clopidogrel (between months 7 and 18), these events occurred in 4.9% after DES versus 1.3% after BMS implantation. Target vessel revascularization remained lower after DES, resulting in similar rates of all clinical events for this time period (DES 9.3%, BMS 7.9%). Documented late stent thrombosis and related death/target vessel MI were twice as frequent after DES versus BMS (2.6% vs. 1.3%). Thrombosis-related events occurred between 15 and 362 days after the discontinuation of clopidogrel, presenting as MI or death in 88%. Conclusions: After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel revascularization is maintained but has to be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
34. Heart Failure With Recovered Ejection Fraction.
- Author
-
Merken, Jort, Brunner-La Rocca, Hans-Peter, Weerts, Jerremy, Verdonschot, Job, Hazebroek, Mark, Schummers, Georg, Schreckenberg, Marcus, Lumens, Joost, Heymans, Stephane, and Knackstedt, Christian
- Subjects
- *
HEART failure , *HEART function tests , *CARDIAC patients , *LEFT heart ventricle , *COMPARATIVE studies , *ECHOCARDIOGRAPHY , *CARDIAC contraction , *HEART physiology , *HOSPITAL care , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *EVALUATION research - Published
- 2018
- Full Text
- View/download PDF
35. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction.
- Author
-
Gandhi, Parul U., Motiwala, Shweta R., Belcher, Arianna M., Gaggin, Hanna K., Weiner, Rory B., Baggish, Aaron L., Fiuzat, Mona, Brunner-La Rocca, Hans-Peter, and Jr.Januzzi, James L.
- Abstract
Background Galectin-3 is a prognostic heart failure biomarker associated with aldosterone-induced myocardial fibrosis; mineralocorticoid receptor antagonists (MRAs) may reduce such fibrosis. We sought to examine outcomes of patients with heart failure with reduced ejection fraction (HFrEF) as a function of galectin-3 and MRA therapy. Methods A total of 151 patients with chronic HFrEF were categorized by baseline galectin-3 and subsequent MRA therapy trends with regard to cardiovascular (CV) events, left ventricular remodeling, safety, and quality of life, over a mean of 10 months. Results Although galectin-3 >20 ng/mL was associated with doubling in adjusted risk for CV events, regardless of MRA treatment, there was no difference in CV event rates with regard to MRA use patterns, independent of galectin-3 concentrations. Specifically, in patients with elevated galectin-3 treated with intensified MRA therapy, a significant difference was not detected in CV event rates ( P = .79) or the cumulative number of such events ( P = .76). Adjusted analysis revealed no difference in time to first CV event if MRA was added/intensified in those with elevated galectin-3 (hazard ratio 0.99, 95% CI 0.97-1.02, P = .74); similarly, cumulative MRA dose was not a specific predictor of benefit. In those with elevated galectin-3, MRA therapy did not affect left ventricular remodeling indices or quality of life at follow-up; these patients had the highest rates of treatment-related adverse events with intensified MRA use. Regardless of MRA use, elevated galectin-3 was associated with more significant renal dysfunction. Conclusions Among patients with chronic HFrEF and elevated galectin-3 concentrations, we found no specific benefit from addition or intensification of MRA therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Reply to letter to the editor entitled “Proposed strategy for optimizing aldosterone blockade in heart failure” by Dr Jolobe.
- Author
-
Maeder, Micha T., Rickli, Hans, Pfisterer, Matthias E., and Brunner-La Rocca, Hans-Peter
- Published
- 2012
- Full Text
- View/download PDF
37. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy.
- Author
-
Maeder, Micha T., Rickli, Hans, Pfisterer, Matthias E., Muzzarelli, Stefano, Ammann, Peter, Fehr, Thomas, Hack, Dietrich, Weilenmann, Daniel, Dieterle, Thomas, Kiencke, Stephanie, Estlinbaum, Werner, and Brunner-La Rocca, Hans-Peter
- Abstract
Background: Incidence, predictors, and prognostic impact of worsening renal function (WRF) in elderly patients with chronic heart failure (HF) undergoing intensive contemporary medical therapy are unknown. Methods and Results: In 566 patients (age 77 ± 8 years) included in the TIME-CHF, serum creatinine (sCr) was repeatedly measured up to 6 months. Worsening renal function was classified as increase in sCr by 0.2 to 0.3 (WRFI), 0.3 to 0.5 (WRFII), or ≥0.5 mg/dL (WRFIII) within the first 6 months. Outcome events were assessed for 18 months. Results: The incidence of WRF I, II, and III was 12%, 19%, and 22%, respectively. Worsening renal function III was associated with increased mortality (hazard ratio 1.98 [95% CI 1.27-3.07, P = .002] vs no WRF), whereas WRF I/II was not. History of renal failure, spironolactone treatment, higher baseline dose, and higher maximal increase in loop diuretic dose were independently associated with the occurrence of WRF III, whereas angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, and β-blocker use and allocation to N-terminal pro–B-type natriuretic peptide–guided management were not. Worsening renal function III was an independent predictor of death, death or hospitalization, and death or HF hospitalization also after adjusting for baseline characteristics. Conclusions: One fifth of elderly patients with chronic HF experienced WRF III on 6-month intensive HF treatment. These patients had higher mortality, whereas patients with smaller sCr rises did not. Occurrence of WRF III was associated with high doses of loop diuretics and spironolactone use but not with other treatments. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
38. The Balance of Risks and Benefits of Drug-Eluting Versus Bare-Metal Stents
- Author
-
Pfisterer, Matthias, Brunner-La Rocca, Hans Peter, and Kaiser, Christoph
- Published
- 2008
- Full Text
- View/download PDF
39. Worsening Renal Function in Heart Failure: It Takes 2 to Tangle.
- Author
-
van Kimmenade, Roland R.J., ten Cate, Tim J., and Brunner-La Rocca, Hans-Peter
- Subjects
- *
HEART failure , *KIDNEY function tests , *ENKEPHALINS , *OPIOID receptors , *PHYSICIANS , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
40. Duty-cycled unipolar/bipolar versus conventional radiofrequency ablation in paroxysmal and persistent atrial fibrillation
- Author
-
Tivig, Christine, Dang, Lam, Brunner-La Rocca, Hans-Peter, Özcan, Sibel, Duru, Firat, and Scharf, Christoph
- Subjects
- *
CATHETER ablation , *ATRIAL fibrillation , *MEDICAL statistics , *MYOCARDIAL depressants , *PULMONARY veins , *ELECTRONOGRAPHY - Abstract
Abstract: Background: Duty-cycled (DC) radiofrequency ablation (RFA) for atrial fibrillation (AF) has been introduced, however, data on large patient series and comparison to conventional RFA are scarce. Methods: Between 2006 and 2008DC RFA was performed in 209 consecutive patients (143 (68%) paroxysmal and 66 (32%) persistent AF). As controls served 211 patients, 155 (73%) with paroxysmal and 56 (27%) with persistent AF (p =0.3). In DC RFA, the pulmonary veins (PV) were isolated followed by ablation at the septum and left atrium, if AF persisted. Conventional PV isolation was followed by anatomical lines at the roof and mitral isthmus. Results: Freedom of paroxysmal AF was demonstrated after 1.08DC RFA procedures per patient in 82% and after 1.19 conventional procedures in 87% after 8.5±6.5months (ns). In persistent AF, success rates were 79% after 1.35DC RFA procedures and 80% after 1.34 conventional procedures after 11.5±8.5months (ns). The subgroup analysis of 119 patients with follow-up ≥12months (17.5 [14.1–23.6] months) showed similar results. Left atrial flutter occurred in 3% and 8% after paroxysmal AF ablation (p <0.05) and in 12% and 23% after persistent AF ablation (p =0.1). Multivariate predictors for success in both groups were age, left atrial size, presence of persistent vs. paroxysmal AF and previous pacemaker implantation, but not the ablation technique used. Non-fatal complications were seen in 2.8% with no differences between the groups. Conclusion: Outcome in DC RFA is similar to conventional RFA with a final success rate exceeding 80% in both paroxysmal and persistent AF in the absence of fatal complications. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
41. Hemodynamic Basis of Exercise Limitation in Patients With Heart Failure and Normal Ejection Fraction
- Author
-
Maeder, Micha T., Thompson, Bruce R., Brunner-La Rocca, Hans-Peter, and Kaye, David M.
- Subjects
- *
HEMODYNAMICS , *HEART failure , *EXERCISE tests , *ECHOCARDIOGRAPHY , *OXYGEN consumption , *LEFT heart ventricle - Abstract
Objectives: The purpose of this study was to invasively investigate the hemodynamic response to exercise in patients with heart failure with normal ejection fraction (HFNEF) and to evaluate the ability of the peak early diastolic transmitral velocity to peak early diastolic annular velocity ratio (E/e′) to reflect exercise hemodynamics. Background: There is little information regarding the hemodynamic response to exercise in HFNEF. Methods: Patients with HFNEF (n = 14) and asymptomatic controls (n = 8) underwent right-side heart catheterization at rest and during supine cycle ergometer exercise and echocardiography with measurement of resting and peak exercise E/e′. Results: Resting pulmonary capillary wedge pressure (PCWP) (10 ± 4 mm Hg vs. 10 ± 4 mm Hg; p = 0.94) was similar in HFNEF patients and controls, but stroke volume index (SVI) (p = 0.02) was lower, and systemic vascular resistance index (SVRI) (p = 0.01) was higher in patients. Patients stopped exercise at lower work rate (0.63 ± 0.29 W/kg vs. 1.13 ± 0.49 W/kg; p = 0.006). Although peak exercise PCWP was similar in both groups (23 ± 6 mm Hg vs. 20 ± 7 mm Hg; p = 0.31), the peak PCWP/work rate ratio was higher in patients compared with controls (46 ± 31 mm Hg/W/kg vs. 20 ± 9 mm Hg/W/kg; p = 0.03). Peak exercise SVI (p = 0.001) was lower and SVRI was higher (p = 0.01) in patients. Resting E/e′ was modestly elevated in patients (13.2 ± 4.1 vs. 9.5 ± 3.4; p = 0.04). Peak exercise E/e′ did not differ between the groups (11.1 ± 3.4 vs. 9.4 ± 3.4; p = 0.28). Conclusions: The HFNEF patients achieved a similar peak exercise PCWP to that of asymptomatic controls, at a much lower workload. This occurs at a lower SVI and in the setting of higher SVRI. The E/e′ does not reflect the hemodynamic changes during exercise in HFNEF patients. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
42. Cerebral cortical microinfarcts: A novel MRI marker of vascular brain injury in patients with heart failure.
- Author
-
Ferro, Doeschka, van den Brink, Hilde, Amier, Raquel, van Buchem, Mark, de Bresser, Jeroen, Bron, Esther, Brunner-La Rocca, Hans-Peter, Hooghiemstra, Astrid, Marcks, Nick, van Rossum, Albert, and Biessels, Geert Jan
- Subjects
- *
HEART failure patients , *BRAIN injuries , *HEART injuries , *CEREBRAL circulation , *COGNITION disorders - Abstract
Patients with heart failure (HF) are at risk for vascular brain injury. Cerebral cortical microinfarcts (CMIs) are a novel MRI marker of vascular brain injury. This study aims to determine the occurrence of CMIs in patient with HF and their clinical correlates, including haemodynamic status. From the Heart-Brain Study, a multicenter prospective cohort study, 154 patients with clinically stable HF without concurrent atrial fibrillation (mean age 69.5 ± 10.1, 32% female) and 124 reference participants without HF (mean age 65.6 ± 7.4, 47% females) were evaluated for CMIs on 3 T MRI. CMI presence in HF was tested for associations with vascular risk profile, cardiac function and history, MRI markers of vascular brain injury and cognitive profile. CMI occurrence was higher in patient with HF (17%) than reference participants (7%); after correction for age and sex OR 2.5 [95% CI 1.1–6.0] p =.032; after additional correction for vascular risk factors OR 2.7 [1.0–7.1] p =.052. In patients with HF, CMI presence was associated with office hypertension (OR 2.7 [1.2–6.5] p =.021) and a lower cardiac index (B = -0.29 [−0.55−−0.04] p =.023 independent of vascular risk factors), but not with cause or duration of HF. Presence of CMIs was not associated with cognitive performance in patients with HF. CMIs are a common occurrence in patients with HF and related to an adverse vascular risk factor profile and severity of cardiac dysfunction. CMIs thus represent a novel marker of vascular brain injury in these patients. • Heart failure is associated with an increased risk for vascular brain injury and cognitive impairment. • Cerebral cortical microinfarcts (CMIs) are a novel MRI-marker of vascular brain injury that is associated with reduced cerebral blood flow and predicts cognitive decline. • In this cohort study we demonstrate that CMIs are very common in patients with heart failure and related to severity of cardiac pump-dysfunction. • Future research must indicate whether CMIs predict cognitive decline over time in patients with heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
43. Initial Imaging-Guided Strategy Versus Routine Care in Patients With Non-ST-Segment Elevation Myocardial Infarction.
- Author
-
Smulders, Martijn W, Kietselaer, Bas L J H, Wildberger, Joachim E, Dagnelie, Pieter C, Brunner-La Rocca, Hans-Peter, Mingels, Alma M A, van Cauteren, Yvonne J M, Theunissen, Ralph A L J, Post, Mark J, Schalla, Simon, van Kuijk, Sander M J, Das, Marco, Kim, Raymond J, Crijns, Harry J G M, and Bekkers, Sebastiaan C A M
- Abstract
Background: Patients with non-ST-segment elevation myocardial infarction and elevated high-sensitivity cardiac troponin levels often routinely undergo invasive coronary angiography (ICA), but many do not have obstructive coronary artery disease.Objectives: This study investigated whether cardiovascular magnetic resonance imaging (CMR) or computed tomographic angiography (CTA) may serve as a safe gatekeeper for ICA.Methods: This randomized controlled trial (NCT01559467) in 207 patients (age 64 years; 62% male patients) with acute chest pain, elevated high-sensitivity cardiac troponin T levels (>14 ng/l), and inconclusive electrocardiogram compared a CMR- or CTA-first strategy with a control strategy of routine clinical care. Follow-up ICA was recommended when initial CMR or CTA suggested myocardial ischemia, infarction, or obstructive coronary artery disease (≥70% stenosis). Primary efficacy and secondary safety endpoints were referral to ICA during hospitalization and 1-year outcomes (major adverse cardiac events and complications), respectively.Results: The CMR- and CTA-first strategies reduced ICA compared with routine clinical care (87% [p = 0.001], 66% [p < 0.001], and 100%, respectively), with similar outcome (hazard ratio: CMR vs. routine, 0.78 [95% confidence interval: 0.37 to 1.61]; CTA vs. routine, 0.66 [95% confidence interval: 0.31 to 1.42]; and CMR vs. CTA, 1.19 [95% confidence interval: 0.53 to 2.66]). Obstructive coronary artery disease after ICA was found in 61% of patients in the routine clinical care arm, in 69% in the CMR-first arm (p = 0.308 vs. routine), and in 85% in the CTA-first arm (p = 0.006 vs. routine). In the non-CMR and non-CTA arms, follow-up CMR and CTA were performed in 67% and 13% of patients and led to a new diagnosis in 33% and 3%, respectively (p < 0.001).Conclusions: A novel strategy of implementing CMR or CTA first in the diagnostic process in non-ST-segment elevation myocardial infarction is a safe gatekeeper for ICA. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
44. sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T.
- Author
-
Emdin, Michele, Aimo, Alberto, Vergaro, Giuseppe, Bayes-Genis, Antoni, Lupón, Josep, Latini, Roberto, Meessen, Jennifer, Anand, Inder S., Cohn, Jay N., Gravning, Jørgen, Gullestad, Lars, Broch, Kaspar, Ueland, Thor, Nymo, Ståle H., Brunner-La Rocca, Hans-Peter, de Boer, Rudolf A., Gaggin, Hanna K., Ripoli, Andrea, Passino, Claudio, and Januzzi, James L.
- Subjects
- *
HEART failure , *TROPONIN , *NEOPLASTIC cell transformation , *HEART fibrosis , *BIOMARKERS - Abstract
Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to inflammation and fibrosis.Objectives: This study assessed the independent prognostic value of sST2 in chronic heart failure (HF).Methods: Individual patient data from studies that assessed sST2 for risk prediction in chronic HF, together with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT), were retrieved.Results: A total of 4,268 patients were evaluated (median age 68 years, 75% males, 65% with ischemic HF, 87% with left ventricular ejection fraction [LVEF] <40%). NT-proBNP, hs-TnT, and sST2 were 1,360 ng/l (interquartile interval: 513 to 3,222 ng/l), 18 ng/l (interquartile interval: 9 to 33 ng/l), and 27 ng/l (interquartile interval: 20 to 39 ng/l), respectively. During a 2.4-year median follow-up, 1,319 patients (31%) experienced all-cause death (n = 932 [22%] for cardiovascular causes). Among the 4,118 patients (96%) with available data, 1,029 (24%) were hospitalized at least once for worsening HF over 2.2 years. The best sST2 cutoff for the prediction of all-cause and cardiovascular death and HF hospitalization was 28 ng/ml, with good performance at Kaplan-Meier analysis (log-rank: 117.6, 61.0, and 88.6, respectively; all p < 0.001). In a model that included age, sex, body mass index, ischemic etiology, LVEF, New York Heart Association functional class, glomerular filtration rate, HF medical therapy, NT-proBNP, and hs-TnT, the risk of all-cause death, cardiovascular death, and HF hospitalization increased by 26%, 25%, and 30%, respectively, per each doubling of sST2. sST2 retained its independent prognostic value across most population subgroups.Conclusions: sST2 yielded strong, independent predictive value for all-cause and cardiovascular mortality, and HF hospitalization in chronic HF, and deserves consideration to be part of a multimarker panel together with NT-proBNP and hs-TnT. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
45. Neighbourhood walkability in relation to cognitive functioning in patients with disorders along the heart-brain axis.
- Author
-
Timmermans, Erik J., Leeuwis, Anna E., Bots, Michiel L., van Alphen, Juliette L., Biessels, Geert Jan, Brunner-La Rocca, Hans-Peter, Kappelle, L. Jaap, van Rossum, Albert C., van Osch, Matthias J.P., and Vaartjes, Ilonca
- Subjects
- *
WALKABILITY , *COGNITIVE ability , *EXECUTIVE function , *COGNITION disorders , *BUILT environment - Abstract
This study examined associations of neighbourhood walkability with cognitive functioning (i.e., global cognition, memory, language, attention-psychomotor speed, and executive functioning) in participants without or with either heart failure, carotid occlusive disease, or vascular cognitive impairment. Neighbourhood walkability at baseline was positively associated with global cognition and attention-psychomotor speed. These associations were stronger in patients with vascular cognitive impairment. Individuals who live in residential areas with higher walkability levels were less likely to have impairments in language and executive functioning at two-year follow-up. These findings highlight the importance of the built environment for cognitive functioning in healthy and vulnerable groups. • We assessed associations of neighbourhood walkability with cognitive functioning. • We did this in reference participants and various heart-brain axis patient groups. • Walkability was positively cross-sectionally associated with global cognition. • Higher walkability lowered the odds of impaired executive functioning at follow-up. • Some associations were stronger in patients with vascular cognitive impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study.
- Author
-
Lupón, Josep, Sanders-van Wijk, Sandra, Januzzi, James L., de Antonio, Marta, Gaggin, Hanna K., Pfisterer, Matthias, Galán, Amparo, Shah, Ravi, Brunner-La Rocca, Hans-Peter, and Bayes-Genis, Antoni
- Subjects
- *
HEART failure treatment , *VENTRICULAR remodeling , *VENTRICULAR ejection fraction , *ETIOLOGY of diseases , *DIASTOLE (Cardiac cycle) , *HEALTH outcome assessment - Abstract
Background Cardiac remodeling and its reversibility are key in HF outcomes. The ST2-R2 score was recently developed to predict relevant left ventricular (LV) reverse remodeling (R2) in patients with heart failure (HF). In the present study we sought to validate the ST2-R2 score for grading improvement in LV ejection fraction (EF) and LV size at one year, and to evaluate its prognostic implication up to 4 years. Methods A total of 569 patients with baseline LVEF < 40% from three international cohorts (Barcelona, TIME-CHF, and PROTECT) were included in the study. Patients were classified into four strata based on their ST2-R2 score, which took into account concentrations of the biomarker ST2, non-ischemic etiology, absence of left bundle branch block, HF duration, baseline LVEF, and β-blocker treatment. Results A significant relationship was observed between ST2-R2 scores and changes in LVEF and indexed LV sizes. LVEF recovery (from + 5.6% to + 17.3%; p < 0.001), percentage reduction in LV end-systolic volume index (from − 6.1% to − 32.1%; p < 0.001) and in LV end-systolic diameter index (from − 1.1% to − 18.6%; p < 0.001) increased over the ST2-R2 strata. A similar trend was observed with diastolic parameters. Improvement in LV function and size was inversely predictive of mortality. Hazard ratios for risk of death, using the lower ST2-R2 score strata (< 9) as a reference, were 0.49 (p < 0.001; score 9–11), 0.27 (p < 0.001; score 12–14), and 0.17 (p < 0.001; score 15–17). Conclusions The ST2-R2 score predicts reverse LV remodeling in HF patients and is useful for predicting mortality up to 4 years. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
47. Clinical Interpretation of Elevated Concentrations of Cardiac Troponin T, but Not Troponin I, in Nursing Home Residents.
- Author
-
Cardinaels, Eline P.M., Daamen, Mariëlle A.M.J., Bekers, Otto, ten Kate, Joop, Niens, Marijke, van Suijlen, Jeroen D.E., van Dieijen-Visser, Marja P., Brunner-La Rocca, Hans-Peter, Schols, Jos M.G.A., and Mingels, Alma M.A.
- Subjects
- *
HEART metabolism , *ELDER care , *GERIATRIC assessment , *BIOMARKERS , *CREATININE , *GLOMERULAR filtration rate , *LONG-term health care , *HEART failure , *LONGITUDINAL method , *MORTALITY , *NURSING home patients , *NURSING care facilities , *PROBABILITY theory , *RISK assessment , *TROPONIN , *ODDS ratio , *OLD age , *DIAGNOSIS , *PROGNOSIS - Abstract
Objective Cardiac troponins T (cTnT) and I (cTnI) are the preferred biomarkers to detect myocardial damage. The present study explores the value of measuring cardiac troponins (cTn) in nursing home residents, by investigating its relation to heart failure and 1-year mortality using 1 cTnT and 2 cTnI assays that are widely used in clinical practice. Design All participants underwent extensive clinical examinations and echocardiographic assessment for the diagnosis of heart failure. cTn was measured using high-sensitive (hs)- cTnT (Roche), hs-cTnI (Abbott), and sensitive cTnI (Beckman) assays. The glomerular filtration rate was estimated (eGFR) using serum creatinine and cystatin C concentrations. Data on all-cause mortality were collected at 1-year follow-up. Participants and Setting Participants were 495 long-term nursing home residents, older than 65 years, of 5 Dutch nursing home organizations. Results Median (IQR) concentrations were 20.6 (17.8–30.6), 6.8 (4.1–12.5), and 4.0 (2.0–8.0) ng/L for hs-cTnT, hs-cTnI, and cTnI, respectively. In total, 79% had elevated hs-cTnT concentrations, whereas only 9% and 5% of hs-cTnI and cTnI concentrations were elevated. Most important and independent determinants for higher hs-cTnT and hs-cTnI concentrations were heart failure and renal dysfunction. Whereas both heart failure (odds ratio [OR] 3.4) and eGFR lower than 60 mL/min/1.73 m 2 (OR 3.6) were equal contributors to higher hs-cTnT concentrations (all P < .001), hs-cTnI and cTnI were less associated with renal dysfunction (OR of, respectively, 1.9 and 2.1; P < .01) in comparison with heart failure (OR 4.3 and 4.7, respectively, P < .001). Furthermore, residents with higher hs-cTnT or hs-cTnI concentrations (fourth quartile) had respectively 4 versus 2 times more risk of 1-year mortality compared with lower concentrations. Conclusion Regardless of their cardiac health, hs-cTnT but not hs-cTnI concentrations were elevated in almost all aged nursing home residents, questioning the use of the current diagnostic cutoff in elderly with high comorbidity. Nonetheless, measuring cardiac troponins, especially hs-cTnT, had a promising role in assessing future risk of mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Prognostic Relevance of Gene-Environment Interactions in Patients With Dilated Cardiomyopathy: Applying the MOGE(S) Classification.
- Author
-
Hazebroek, Mark R., Moors, Suzanne, Dennert, Robert, van den Wijngaard, Arthur, Krapels, Ingrid, Hoos, Marije, Verdonschot, Job, Merken, Jort J., de Vries, Bart, Wolffs, Petra F., Crijns, Harry J.G.M., Brunner-La Rocca, Hans-Peter, and Heymans, Stephane
- Subjects
- *
GENOTYPE-environment interaction , *DILATED cardiomyopathy , *ETIOLOGY of diseases , *MEDICAL registries , *BIOPSY , *PROGNOSIS , *PATIENTS , *PHENOTYPES , *SEVERITY of illness index , *DIAGNOSIS - Abstract
Background: The multifactorial pathogenesis leading to dilated cardiomyopathy (DCM) makes stratification difficult. The recent MOGE(S) (morphofunctional, organ involvement, genetic or familial, etiology, stage) classification addresses this issue.Objectives: The purpose of this study was to investigate the applicability and prognostic relevance of the MOGE(S) classification in patients with DCM.Methods: This study used patients from the Maastricht Cardiomyopathy Registry in the Netherlands and excluded patients with ischemic, valvular, hypertensive, and congenital heart disease. All other patients underwent a complete diagnostic work-up, including genetic evaluation and endomyocardial biopsy.Results: A total of 213 consecutive patients with DCM were included: organ involvement was demonstrated in 35 (16%) and genetic or familial DCM in 70 (33%) patients, including 16 (8%) patients with a pathogenic mutation. At least 1 cause was found in 155 (73%) patients, of whom 48 (23%) had more than 1 possible cause. Left ventricular reverse remodeling was more common in patients with nongenetic or nonfamilial DCM than in patients with genetic or familial DCM (40% vs. 25%; p = 0.04). After a median follow-up of 47 months, organ involvement and higher New York Heart Association functional class were associated with adverse outcome (p < 0.001 and p = 0.02, respectively). Genetic or familial DCM per se was of no prognostic significance, but when it was accompanied by additional etiologic-environmental factors such as significant viral load, immune-mediated factors, rhythm disturbances, or toxic triggers, a worse outcome was revealed (p = 0.03). A higher presence of MOGE(S) attributes (≥2 vs. ≤1 attributes) showed an adverse outcome (p = 0.007).Conclusions: The MOGE(S) classification in DCM is applicable, and each attribute or the gene-environment interaction is associated with outcome. Importantly, the presence of multiple attributes was a strong predictor of adverse outcome. Finally, adaptation of the MOGE(S) involving multiple possible etiologies is recommended. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
49. Multimarker Strategy for Short-Term Risk Assessment in Patients With Dyspnea in the Emergency Department: The MARKED (Multi mARKer Emergency Dyspnea)-Risk Score
- Author
-
Eurlings, Luc W., Sanders-van Wijk, Sandra, van Kimmenade, Roland, Osinski, Aart, van Helmond, Lidwien, Vallinga, Maud, Crijns, Harry J., van Dieijen-Visser, Marja P., Brunner-La Rocca, Hans-Peter, and Pinto, Yigal M.
- Subjects
- *
DYSPNEA , *CARDIOVASCULAR emergencies , *TROPONIN , *BIOMARKERS , *SYSTOLIC blood pressure , *MORTALITY , *HEART failure , *BLOOD urea nitrogen , *DISEASE risk factors - Abstract
Objectives: The study aim was to determine the prognostic value of a multimarker strategy for risk-assessment in patients presenting to the emergency department (ED) with dyspnea. Background: Combining biomarkers with different pathophysiological backgrounds may improve risk stratification in dyspneic patients in the ED. Methods: The study prospectively investigated the prognostic value of the biomarkers N-terminal pro–B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive protein (hs-CRP), and Galectin-3 (Gal-3) for 90-day mortality in 603 patients presenting to the ED with dyspnea as primary complaint. Results: hs-CRP, hs-cTnT, Cyst-C, and NT-proBNP were independent predictors of 90-day mortality. The number of elevated biomarkers was highly associated with outcome (odds ratio: 2.94 per biomarker, 95% confidence interval [CI]: 2.29 to 3.78, p < 0.001). A multimarker approach had incremental value beyond a single-marker approach. Our multimarker emergency dyspnea-risk score (MARKED-risk score) incorporating age ≥75 years, systolic blood pressure <110 mm Hg, history of heart failure, dyspnea New York Heart Association functional class IV, hs-cTnT ≥0.04 μg/l, hs-CRP ≥25 mg/l, and Cys-C ≥1.125 mg/l had excellent prognostic performance (area under the curve: 0.85, 95% CI: 0.81 to 0.89), was robust in internal validation analyses and could identify patients with very low (<3 points), intermediate (≥3, <5 points), and high risk (≥5 points) of 90-day mortality (2%, 14%, and 44% respectively; p < 0.001). Conclusions: A multimarker strategy provided superior risk stratification beyond any single-marker approach. The MARKED-risk score that incorporates hs-cTnT, hs-CRP, and Cys-C along with clinical risk factors accurately identifies patients with very low, intermediate, and high risk. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
50. Frequency and Predictors of Hyperkalemia in Patients ≥60 Years of Age With Heart Failure Undergoing Intense Medical Therapy
- Author
-
Muzzarelli, Stefano, Maeder, Micha Tobias, Toggweiler, Stefan, Rickli, Hans, Nietlispach, Fabian, Julius, Barbara, Burkard, Thilo, Pfisterer, Matthias Emil, and Brunner-La Rocca, Hans-Peter
- Subjects
- *
HYPERKALEMIA , *OLDER patients , *CONGESTIVE heart failure , *SERUM , *HEART failure treatment , *MEDICAL statistics - Abstract
Hyperkalemia is a concern in heart failure (HF), especially in older patients with co-morbidities. Previous studies addressing this issue have focused mainly on younger patients. This study was aimed at determining the frequency and predictors of hyperkalemia in older patients with HF undergoing intense medical therapy. Frequency and predictors of hyperkalemia were defined in patients (n = 566) participating in the Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure, in which patients ≥60 years of age were randomized to a standard versus an intensified N-terminal brain natriuretic peptide-guided HF therapy. During an 18-month follow-up 76 patients (13.4%) had hyperkalemia (≥5.5 mmol/L) and 28 (4.9%) had severe hyperkalemia (≥6.0 mmol/L). Higher baseline serum potassium (odds ratio [OR] 2.92 per mmol/L), baseline creatinine (OR 1.11 per 10 μmol/L), gout (OR 2.56), New York Heart Association (NYHA) class (compared to NYHA class II, IV OR 3.08), higher dosage of spironolactone at baseline (OR 1.20 per 12.5 mg/day), and higher dose changes of spironolactone (compared to no dose change: 12.5 mg, OR 1.45; 25 mg, OR 2.52; >25 mg, OR 3.24) were independent predictors for development of hyperkalemia (p <0.05 for all comparisons). In conclusion, hyperkalemia is common in patients ≥60 years of age with HF undergoing intense medical therapy. Risk is increased in patients treated with spironolactone, in addition to patient-specific risk factors such as chronic kidney disease, higher serum potassium, advanced NYHA class, and gout. Careful surveillance of serum potassium and cautious use of spironolactone in patients at risk may help to decrease the incidence of potentially hazardous complications caused by hyperkalemia. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.